AlphaMeld Corporation, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, announced the continuation and expansion of its collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin), a Japan-based global specialty pharmaceutical company. The enhanced partnership provides enterprise-wide access to AlphaMeld Corporation’s proprietary AI-powered AlphaMeld® platform, further accelerating Kyowa Kirin’s innovative drug discovery and development initiatives.
The AlphaMeld platform empowers key functional stakeholders, including those involved in early drug discovery, target identification, competitive intelligence, and clinical trial optimization. By extracting actionable insights from vast, diverse datasets, the platform accelerates the identification of novel therapeutic opportunities across various disease areas. This expanded partnership builds on the success of previous collaborations, underscoring Kyowa Kirin’s commitment to leveraging advanced AI, machine learning, and generative AI technologies to address unmet medical needs globally.
“Kyowa Kirin’s forward-looking approach to adopting transformative technologies aligns seamlessly with our mission to accelerate the development of life-saving therapies,” said Krishnan Nandabalan, Ph.D., President and CEO at AlphaMeld Corporation. “Expanding their access to AlphaMeld reflects the tangible outcomes achieved through our collaboration to date and underscores the growing demand for enterprise-grade AI solutions in the pharmaceutical industry,” he added.
こちらもお読みください： プリモ、アジア太平洋地域でプレシジョン・オンコロジーを推進するためシャインと提携
The expanded agreement will allow Kyowa Kirin’s global research and development teams to seamlessly integrate the AlphaMeld platform, widely recognized as the de facto standard in the pharmaceutical industry, into their workflows. This will facilitate data-driven decisions and streamline the drug development process. The collaboration exemplifies a shared commitment to innovation, with both companies striving to transform the future of medicine.
“The longstanding collaboration with AlphaMeld Corporation and the enterprise-wide integration of the AlphaMeld platform is a significant milestone in Kyowa Kirin’s pursuit of digital innovation to deliver innovative therapies,” said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Global Research Head, Kyowa Kirin Co., Ltd. “The advanced capabilities of AlphaMeld Corporation will empower our teams to identify novel therapeutic opportunities with unprecedented speed, precision, and an increased probability of clinical success, supporting our mission to address unmet medical needs and bring smiles to patients.”
ソース GlobeNewswire
